Live Analyst Rating Changes 1515 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Constantine Davides
CJ
Constantine Davides
Citizens JMP
Wall Street Analyst
★☆☆☆☆
#2529
on 13Foresight · ranked by our own returns
40%
Success Rate
-14.3%
Average Return
12 of 30 calls profitable · -31.1% vs benchmark
📈 Across the calls we could measure, roughly 40% of Constantine Davides's ratings turned a profit when each position was held for 1 year — averaging -14.3% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

36 Buy 4 Hold 0 Sell
Constantine's Stock Coverage 34 ratings · 2026-06-19
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return
HQY
Healthequity
 Jun 01, 2026 BUY Strong Buy
+33.4% avg upside
20 analysts
$111.00
30.31% Upside
 -5.5%
PGNY
Progyny
 May 11, 2026 BUY Strong Buy
+11.9% avg upside
14 analysts
$31.00
18.82% Upside
 +14.9%
OMDA
Omada Health, Inc.
 May 08, 2026 BUY Strong Buy
+32.0% avg upside
11 analysts
$21.00
19.15% Upside
 +17.9%
USPH
US Physical Therapy
 May 08, 2026 BUY Strong Buy
+44.7% avg upside
12 analysts
$98.00
54.76% Upside
 +7.8%
CCRN
Cross Country Healthcare
 May 07, 2026 HOLD Hold
+20.0% avg upside
15 analysts
 — +0.0%
ADUS
Addus Homecare
 May 06, 2026 BUY Strong Buy
+35.9% avg upside
18 analysts
$142.00
50.75% Upside
 -3.3%
OPCH
Option Care Health
 Apr 30, 2026 BUY Strong Buy
+34.9% avg upside
20 analysts
$32.00
45.44% Upside
 +6.8%
AMN
AMN Healthcare Services
 Feb 23, 2026 BUY Buy
+35.2% avg upside
14 analysts
$24.00
22.51% Downside
 +37.5%
WAY
Waystar Holding Corp.
 Feb 18, 2026 BUY Strong Buy
+106.0% avg upside
29 analysts
$34.00
84.04% Upside
 -27.5%
EVH
Evolent Health
 Jan 06, 2026 BUY Strong Buy
+121.1% avg upside
19 analysts
$10.00
122.65% Upside
 +5.0%
PRVA
Privia Health Group
 Nov 07, 2025 BUY Strong Buy
+34.1% avg upside
26 analysts
$31.00
31.06% Upside
 -7.7%
OPRX
OptimizeRx
 Nov 07, 2025 BUY Strong Buy
+158.1% avg upside
9 analysts
$24.00
381.92% Upside
 -68.4%
SLP
Simulations Plus
 Jul 15, 2025 HOLD Buy
+89.9% avg upside
11 analysts
 — +25.8%
CERT
Certara
 May 06, 2025 HOLD Buy
+133.3% avg upside
21 analysts
 — -44.9%
AGL
Agilon Health
 Apr 28, 2025 HOLD Buy
-59.1% avg upside
26 analysts
 — -70.9%
HSTM
HealthStream
 Feb 25, 2025 HOLD Buy
+17.0% avg upside
8 analysts
 — -32.8%
BNGO
BioNano Genomics
 May 25, 2023 BUY Strong Buy
+724.8% avg upside
9 analysts
$17.50
1435.04% Upside
 -83.5%
SCNX
Scienture Holdings
 May 16, 2023 BUY Strong Buy
+2732.0% avg upside
4 analysts
$18.75
4810.98% Upside
 +70.1%
LGVN
Longeveron
 May 16, 2023 BUY Strong Buy
+5427.8% avg upside
4 analysts
$125.00
15142.02% Upside
 -95.7%
ELMD
Electromed
 May 11, 2023 BUY Strong Buy
-14.4% avg upside
6 analysts
$15.00
61.22% Downside
 +44.9%
INVA
Innoviva
 May 10, 2023 BUY Buy
+27.2% avg upside
12 analysts
$22.50
0.02% Downside
 +27.9%
NNVC
NanoViricides
 Apr 18, 2023 BUY Strong Buy
+301.8% avg upside
2 analysts
$5.25
274.97% Upside
 -16.3%
NMRD
Nemaura Medical
 Mar 30, 2023 BUY Strong Buy
+3749900.0% avg upside
3 analysts
$6.00
5999899.95% Upside
 ·
CCLD
CareCloud
 Mar 20, 2023 BUY Strong Buy
+282.7% avg upside
9 analysts
$8.50
289.95% Upside
 -61.4%
VNRX
VolitionRX
 Mar 16, 2023 BUY Strong Buy
+589.8% avg upside
11 analysts
$6.00
319.68% Upside
 -44.2%
GRCE
Grace Therapeutics
 Feb 15, 2023 BUY Strong Buy
+153.0% avg upside
9 analysts
$15.00
530.24% Upside
 -20.3%
RKTO
Rocket One
 Dec 30, 2022 BUY Strong Buy
+905.3% avg upside
8 analysts
$33.00
2955.59% Upside
 ·
BBLG
Bone Biologics
 Oct 18, 2022 BUY Strong Buy
+4523.2% avg upside
2 analysts
$67.50
4523.19% Upside
 ·
BIVI
BioVie
 Sep 28, 2022 BUY Buy
+847.0% avg upside
6 analysts
$8.00
354.64% Upside
 +23.8%
ISPC
iSpecimen
 Sep 23, 2022 BUY Strong Buy
+64.1% avg upside
3 analysts
$4.25
64.08% Upside
 -68.0%
KTTA
Pasithea Therapeutics Corp
 Aug 18, 2022 BUY Strong Buy
+2919.9% avg upside
3 analysts
$2.30
359.93% Upside
 -54.6%
HCTI
Healthcare Triangle
 Mar 14, 2022 BUY Strong Buy
+82.7% avg upside
1 analyst
$4.00
82.69% Upside
 ·
GMVDF
G Medical Innovations Holdings
 Jan 18, 2022 BUY Strong Buy
+209999899.9% avg upside
1 analyst
$210.00
209999899.95% Upside
 ·
MMS
Maximus
 Sep 27, 2011 BUY Buy
+20.6% avg upside
6 analysts
$41.00
26.39% Downside
 +74.4%
🔒 29 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Constantine Davides — Frequently Asked Questions
How accurate are Constantine Davides's stock ratings?
Based on the calls 13Foresight could measure, about 40% of Constantine's ratings were profitable over a one-year hold, with an average return of -14.3% per rating, or -31.1% versus the S&P 500. We score every analyst the same way, from historical prices.
How is Constantine ranked on 13Foresight?
Constantine Davides is currently ranked #2529 with a 1-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Constantine cover?
Constantine most recently has ratings on HQY, PGNY, OMDA, USPH, CCRN, ADUS, OPCH, AMN, WAY, EVH, PRVA, OPRX and 22 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.